Co-Authors
This is a "connection" page, showing publications co-authored by XIN SHELLEY WANG and LORETTA A WILLIAMS.
Connection Strength
1.064
-
Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep. Eur J Oncol Nurs. 2021 Jun; 52:101959.
Score: 0.195
-
Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol. 2019 03; 152(3):492-500.
Score: 0.168
-
Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
Score: 0.136
-
Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.
Score: 0.118
-
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012 Jul; 26(5):699-705.
Score: 0.102
-
Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010 Apr 15; 116(8):2053-63.
Score: 0.091
-
Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74.
Score: 0.090
-
Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008 Oct 15; 113(8):2102-9.
Score: 0.082
-
Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1531-40.
Score: 0.028
-
Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013 Feb 05; 6:13.
Score: 0.028
-
Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer. 2013 Jan 15; 119(2):411-20.
Score: 0.027